Verastem Inc (FRA:2VSA)
€ 4.06 0.24 (6.28%) Market Cap: 193.89 Mil Enterprise Value: 145.66 Mil PE Ratio: 0 PB Ratio: 16.62 GF Score: 35/100

Verastem Inc VSTM LGSOC Program Update Call Transcript

Jan 24, 2023 / 11:00PM GMT
Release Date Price: €6.42 (+0.11%)
Operator

Good evening, and welcome to the Verastem Oncology Investor Conference Call on Tuesday, January 24, 2023. (Operator Instructions) Please be advised that this call is being recorded at the company's request and will be available on the company's website for a period of 90 days from today.

At this time, I would like to introduce Mr. Daniel Calkins, Vice President of Investor Relations and Finance at Verastem Oncology. Please go ahead.

Daniel Calkins
Verastem, Inc. - Interim Principal Accounting Officer & Financial Officer

Thank you. Hello. Welcome, everyone, and thank you for joining us today to discuss the interim data from Part A of the ongoing RAMP 201 international registration-directed Phase II study evaluating the safety and efficacy of avutometinib alone and in combination with defactinib among patients with recurrent low-grade serous ovarian cancer, which will be -- which we will be referring to today as LGSOC. The company will also provide our regulatory update following a productive meeting with the FDA.

Today's speakers include

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot